Substrate recognition by the 4‐hydroxytryptamine kinase <scp>PsiK in</scp> psilocybin biosynthesis

Psilocybin, the natural hallucinogen from Psilocybe (magic) mushrooms, is a highly promising drug candidate for the treatment of depression and several other mental health conditions. Biosynthesis of psilocybin from the amino acid l-tryptophan involves four strictly sequential modifications. The third of these, ATP-dependent phosphorylation of the intermediate 4-hydroxytryptamine, is catalysed by PsiK. Here we present a crystallographic analysis and a structure-based mutagenesis study of this kinase, providing insight into its mode of substrate recognition. The results of our work will support future bioengineering efforts aimed at generating variants of psilocybin with enhanced therapeutic properties.

Authors

Institutions

Publication Details

Journal
FEBS Letters
Published
2024-10-24
DOI
https://doi.org/10.1002/1873-3468.15042
Citations
4
Primary Topic
Psychedelics and Drug Studies
Type
article
Field-Weighted Citation Impact
2.56

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Substrate recognition by the 4‐hydroxytryptamine kinase PsiK in psilocybin biosynthesis

Sebastiaan Werten, Dirk Hoffmeister, Bernhard Rupp, Kai Rogge et al.
4 citations
FEBS Letters
Psychedelics and Drug Studies
2.56
article

Substrate recognition by the 4‐hydroxytryptamine kinase PsiK in psilocybin biosynthesis

Sebastiaan Werten, Dirk Hoffmeister, Bernhard Rupp, Kai Rogge, Tobias Wagner
article en
4 citations

Abstract

Psilocybin, the natural hallucinogen from Psilocybe (magic) mushrooms, is a highly promising drug candidate for the treatment of depression and several other mental health conditions. Biosynthesis of psilocybin from the amino acid l-tryptophan involves four strictly sequential modifications. The third of these, ATP-dependent phosphorylation of the intermediate 4-hydroxytryptamine, is catalysed by PsiK. Here we present a crystallographic analysis and a structure-based mutagenesis study of this kinase, providing insight into its mode of substrate recognition. The results of our work will support future bioengineering efforts aimed at generating variants of psilocybin with enhanced therapeutic properties.

FEBS LettersVol. 599(3)
Universität Innsbruck (AT), Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e. V. - Hans-Knöll-Institut (HKI) (DE), Friedrich Schiller University Jena (DE)
Friedrich-Schiller-Universität Jena, Deutsche Forschungsgemeinschaft, European Synchrotron Radiation Facility, Austrian Science Fund
Good health and well-being
Openalex Percentile: Top 11%
Psychedelics and Drug Studies
2.56
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Substrate recognition by the 4‐hydroxytryptamine kinase <scp>PsiK in</scp> psilocybin biosynthesis — Sebastiaan Werten, Dirk Hoffmeister, et al. · FEBS Letters (2024) | TGRS Research Map | TGRS